Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma.
The widespread availability of functional imaging in clinical practice has revolutionized the care (staging, response assessment, surveillance) of patients with lymphoma. Using positron emission tomography/computed tomography (PET/CT) with fludeoxyglucose F 18 (FDG), the potential exists for prognostic risk stratification and therapeutic adjustment. This review focuses on personalization of therapy using these 2 modalities in 2 lymphoma subtypes: diffuse large B-cell lymphoma and Hodgkin lymphoma.